Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -20.76% is 149% below its 5-year average of -8.33%, around the middle of its 5-year range (-205.07%–71.29%).
23.04% above its 12-month average of -26.97%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -30.71%.
EBITDA MARGIN
-20.76%
EBITDA MARGIN AVG TTM
-26.97%
EBITDA MARGIN AVG 3Y
-22.15%
EBITDA MARGIN AVG 5Y
-8.33%
EBITDA MARGIN AVG 10Y
4.01%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+23.04%
CURRENT VS 3Y AVG
+6.28%
CURRENT VS 5Y AVG
-149.24%
CURRENT VS 10Y AVG
-617.50%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Fulgent Genetics, Inc.
Market Cap
$583.63M
EBITDA Margin
-20.76%
TTM Avg
-26.97%
3Y Avg
-22.15%
5Y Avg
-8.33%
Market Cap
$583.31M
EBITDA Margin
-3.28%
TTM Avg
-4.19%
3Y Avg
-6.19%
5Y Avg
-9.77%
Market Cap
$579.04M
EBITDA Margin
-155.10%
TTM Avg
-103.66%
3Y Avg
-79.43%
5Y Avg
-77.63%
Market Cap
$597.67M
EBITDA Margin
-5.39%
TTM Avg
-5.12%
3Y Avg
-17.61%
5Y Avg
-12.23%
Market Cap
$569.77M
EBITDA Margin
52.98%
TTM Avg
1.13%
3Y Avg
-15499.35%
5Y Avg
-14628.26%
Market Cap
$601.66M
EBITDA Margin
40.74%
TTM Avg
33.91%
3Y Avg
-21.02%
5Y Avg
1.67%
Market Cap
$561.67M
EBITDA Margin
-27.54%
TTM Avg
-4.08%
3Y Avg
-49.61%
5Y Avg
-102.69%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | $583.63M | -20.76% | -26.97% | -22.15% | -8.33% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | -3.28% | -4.19% | -6.19% | -9.77% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $579.04M | -155.10% | -103.66% | -79.43% | -77.63% |
| AngioDynamics, Inc. (ANGO)vs › | $597.67M | -5.39% | -5.12% | -17.61% | -12.23% |
| CorMedix Inc. (CRMD)vs › | $569.77M | 52.98% | 1.13% | -15499.35% | -14628.26% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $601.66M | 40.74% | 33.91% | -21.02% | 1.67% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -27.54% | -4.08% | -49.61% | -102.69% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $615.00M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $548.99M | N/A | N/A | N/A | N/A |
Gross Margin
35.6%
EBITDA Margin
-20.8%
Operating Margin
-28.2%
Net Margin
-26.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -30.71% |
| 2026-03-31 | -40.23% |
| 2025-12-31 | -36.15% |
| 2025-09-30 | -11.08% |
| 2025-06-30 | -16.70% |
| 2025-03-31 | -18.89% |
| 2024-12-31 | -13.05% |
| 2024-09-30 | -15.55% |
| 2024-06-30 | -17.95% |
| 2024-03-31 | -23.47% |
| 2023-12-31 | -205.07% |
| 2023-09-30 | 7.83% |
| 2023-06-30 | -19.88% |
| 2023-03-31 | -27.12% |
| 2022-12-31 | -39.51% |
| 2022-09-30 | 9.63% |
| 2022-06-30 | 16.87% |
| 2022-03-31 | 64.52% |
| 2021-12-31 | 61.52% |
| 2021-09-30 | 71.29% |
| 2021-06-30 | 65.95% |
| 2021-03-31 | 74.80% |
| 2020-12-31 | 76.97% |
| 2020-09-30 | 63.16% |
| 2020-06-30 | 18.47% |
| 2020-03-31 | -17.35% |
| 2019-12-31 | 1.78% |
| 2019-09-30 | 19.45% |
| 2019-06-30 | 9.57% |
| 2019-03-31 | -23.99% |
| 2018-12-31 | -8.65% |
| 2018-09-30 | -5.32% |
| 2018-06-30 | -8.13% |
| 2018-03-31 | -36.06% |
| 2017-12-31 | -37.30% |
| 2017-09-30 | -23.16% |
| 2017-06-30 | 5.50% |
| 2017-03-31 | 11.89% |
| 2016-12-31 | 28.68% |
| 2016-09-30 | -7.82% |
| 2016-06-30 | 30.67% |
| 2016-03-31 | -12.09% |
| 2015-12-31 | -246.60% |
| 2015-09-30 | 46.51% |
| 2015-06-30 | 39.89% |
| 2015-03-31 | 31.17% |
